Mohammed Nooruddin Meah

Mohammed Nooruddin Meah

Auto-generated profile, based on publicly available information

Mohammed Nooruddin Meah

BHF Centre of Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Circulation
Verified
Journal Article
Open access
PDF file
ABAnda Bularga
Anda Bularga
JHJohn Hung
John Hung
MDMarwa Daghem
Marwa Daghem
SSStacey Stewart
Stacey Stewart
CTCaelan Taggart
Caelan Taggart
ACAndrew Chapman
Andrew Chapman
Background: Type 2 myocardial infarction is caused by myocardial oxygen supply-demand imbalance, and its diagnosis is increasingly common with the advent of high-sensitivity cardiac troponin assays. Although this diagnosis is associated with poor outcomes, widespread uncertainty and confusion remain among clinicians as to how to investigate and manage this heterogeneous group of patients with type 2 myocardial infarction. Methods: In a prospective cohort study, 8064 consecutive patients with increased cardiac troponin concentrations were screened to identify patients with type 2 myocardial infarction. We excluded patients with frailty or renal or hepatic failure. All study participants underwent coronary (invasive or computed tomography angiography) and cardiac (magnetic resonance or echocardiography) imaging, and the underlying causes of infarction were independently adjudicated. The primary outcome was the prevalence of coronary artery disease. Results: In 100 patients with a provisional diagnosis of type 2 myocardial infarction (median age, 65 years [interquartile range, 55–74 years]; 43% women), coronary and cardiac imaging reclassified the diagnosis in 7 patients: type 1 or 4b myocardial infarction in 5 and acute myocardial injury in 2 patients. In those with type 2 myocardial infarction, median cardiac troponin I concentrations were 195 ng/L (interquartile range, 62–760 ng/L) at presentation and 1165 ng/L (interquartile range, 277–3782 ng/L) on repeat testing. The prevalence of coronary artery disease was 68% (63 of 93), which was obstructive in 30% (28 of 93). Infarct-pattern late gadolinium enhancement or regional wall motion abnormalities were observed in 42% (39 of 93), and left ventricular systolic dysfunction was seen in 34% (32 of 93). Only 10 patients had both normal coronary and normal cardiac imaging. Coronary artery disease and left ventricular systolic dysfunction were previously unrecognized in 60% (38 of 63) and 84% (27 of 32), respectively, with only 33% (21 of 63) and 19% (6 of 32) on evidence-based treatments. Conclusions: Systematic coronary and cardiac imaging of patients with type 2 myocardial infarction identified coronary artery disease in two-thirds and left ventricular systolic dysfunction in one-third of patients. Unrecognized and untreated coronary or cardiac disease is seen in most patients with type 2 myocardial infarction, presenting opportunities for initiation of evidence-based treatments with major potential to improve clinical outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03338504.

1 December 2020 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
MDMhairi K. Doris
Mhairi K. Doris
MMMohammed N. Meah
Mohammed N. Meah
AMAlastair James Moss
Alastair James Moss
JAJack P.M. Andrews
Jack P.M. Andrews
RBRong Bing
Rong Bing
PAPhilip D. Adamson
Philip D. Adamson
Background: Positron emission tomography (PET) using 18 F-sodium fluoride ( 18 F-fluoride) to detect microcalcification may provide insight into disease activity in coronary atherosclerosis. This study aimed to investigate the relationship between 18 F-fluoride uptake and progression of coronary calcification in patients with clinically stable coronary artery disease. Methods: Patients with established multivessel coronary atherosclerosis underwent 18 F-fluoride PET-computed tomography angiography and computed tomography calcium scoring, with repeat computed tomography angiography and calcium scoring at one year. Coronary PET uptake was analyzed qualitatively and semiquantitatively in diseased vessels by measuring maximum tissue-to-background ratio. Coronary calcification was quantified by measuring calcium score, mass, and volume. Results: In a total of 183 participants (median age 66 years, 80% male), 116 (63%) patients had increased 18 F-fluoride uptake in at least one vessel. Individuals with increased 18 F-fluoride uptake demonstrated more rapid progression of calcification compared with those without uptake (change in calcium score, 97 [39–166] versus 35 [7–93] AU; P <0.0001). Indeed, the calcium score only increased in coronary segments with 18 F-fluoride uptake (from 95 [30–209] to 148 [61–289] AU; P <0.001) and remained unchanged in segments without 18 F-fluoride uptake (from 46 [16–113] to 49 [20–115] AU; P =0.329). Baseline coronary 18 F-fluoride maximum tissue-to-background ratio correlated with 1-year change in calcium score, calcium volume, and calcium mass (Spearman ρ=0.37, 0.38, and 0.46, respectively; P <0.0001 for all). At the segmental level, baseline 18 F-fluoride activity was an independent predictor of calcium score at 12 months ( P <0.001). However, at the patient level, this was not independent of age, sex, and baseline calcium score ( P =0.50). Conclusions: Coronary 18 F-fluoride uptake identifies both patients and individual coronary segments with more rapid progression of coronary calcification, providing important insights into disease activity within the coronary circulation. At the individual patient level, total calcium score remains an important marker of disease burden and progression. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02110303.

10 July 2024 in JACC: Cardiovascular Imaging
Verified
Journal Article
Open access
MMMichael McDermott
Michael McDermott
MMMohammed N. Meah
Mohammed N. Meah
PKPhyo Khaing
Phyo Khaing
KWKang-Ling Wang
Kang-Ling Wang
JRJennifer Ramsay
Jennifer Ramsay
DNDavid Newby
David Newby
Coronary artery disease continues to be the leading cause of death globally. Identifying patients who are at risk of coronary artery disease remains a public health priority. At present, the focus of cardiovascular disease prevention relies heavily on probabilistic risk scoring despite no randomized controlled trials demonstrating their efficacy. The concept of using imaging to guide preventative therapy is not new, but has previously focused on indirect measures such as carotid intima-media thickening or coronary artery calcification. In recent trials, patients found to have coronary artery disease on computed tomography (CT) coronary angiography were more likely to be started on preventative therapy and had lower rates of cardiac events. This led to the design of the SCOT-HEART 2 (Scottish Computed Tomography of the Heart 2) trial, which aims to determine whether screening with the use of CT coronary angiography is more clinically effective than cardiovascular risk scoring to guide the use of primary preventative therapies and reduce the risk of myocardial infarction.

1 July 2021 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Open access
MMMohammed N. Meah
Mohammed N. Meah
TSTrisha Singh
Trisha Singh
MWMichelle C. Williams
Michelle C. Williams
MDMarc R. Dweck
Marc R. Dweck
DNDavid E. Newby
David E. Newby
DDDamini Dey
Damini Dey
The ability to characterize and to quantify the extent of coronary artery disease has the potential to improve the prognostic capability of coronary computed tomography angiography. Although reproducible techniques have been described in those with mild coronary disease, this has yet to be assessed in patients with advanced disease. Twenty patients with known multivessel disease underwent repeated computed tomography coronary angiography, 2 weeks apart. Coronary artery segments were analysed using semi-automated software by two trained observers to determine intraobserver, interobserver and interscan reproducibility. Overall, 149 coronary arterial segments were analysed. There was excellent intraobserver and interobserver agreement for all plaque volume measurements (Lin's coefficient 0.95 to 1.0). There were no substantial interscan differences (P ​> ​0.05 for all) for total (2063 ​± ​1246 ​mm3, mean of differences -35.6 ​mm3), non-calcified (1795 ​± ​910 ​mm3, mean of differences -4.3 ​mm3), calcified (298 ​± ​425 ​mm3, mean of differences -31.3 ​mm3) and low-attenuation (13 ​± ​13 ​mm3, mean of differences -2.6 ​mm3) plaque volumes. Interscan agreement was highest for total and noncalcified plaque volumes. Calcified and low-attenuation plaque (-236.6 to 174 ​mm3 and -15.8 to 10.5 ​mm3 respectively) had relatively wider 95% limits of agreement reflecting the lower absolute plaque volumes. In the presence of advanced coronary disease, semi-automated plaque quantification provides excellent reproducibility, particularly for total and non-calcified plaque volumes. This approach has major potential to assess change in disease over time and optimize risk stratification in patients with established coronary artery disease.

15 June 2022 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MMMohammed N. Meah
Mohammed N. Meah
ETEvangelos Tzolos
Evangelos Tzolos
KWKang-Ling Wang
Kang-Ling Wang
ABAnda Bularga
Anda Bularga
MDMarc R. Dweck
Marc R. Dweck
CRCarl Roobottom
Carl Roobottom

1 June 2020 in The Lancet
Verified
Journal Article
Open access
MMMohammed N Meah
Mohammed N Meah
MDMartin A Denvir
Martin A Denvir
NMNicholas Linton Mills
Nicholas Linton Mills
JNJohn Norrie
John Norrie
DNDavid Newby
David Newby